Multiple-component solid phases containing at least one active pharmaceutical ingredient
AssigneesUniversity of South Florida, The Regents of the University of Michigan
InventorsMichael J. Zaworotko, Nair Rodriguez-Hornedo, Brian Moulton
Life of this patent
Estimating the term…
Abstract
The subject invention concerns a method for identifying complementary chemical functionalities to form a desired supramolecular synthon. The subject invention also pertains to multiple-component phase compositions comprising one or more pharmaceutical entities and methods for producing such compositions.
Claims26
A multiple-component phase composition comprising a solid phase that is sustained by intermolecular interactions between two or more independent molecular entities, wherein at least one of said two or more independent molecular entities is a pharmaceutical molecule.
(canceled)
6-8. (canceled)
19-24. (canceled)
A method for identifying complementary chemical functionalities in order to form a desired supramolecular synthon, said method comprising:
- (a) evaluating the structure of an active pharmaceutical ingredient;
- (b) determining whether the active pharmaceutical ingredient contains chemical functionalities capable of forming supramolecular synthons with itself;
- (c) identifying from a plurality of chemical functionalities that are known to form a supramolecular synthon at least one functionality that will form a further supramolecular synthon to the supramolecular synthon formed by the active pharmaceutical ingredient, wherein the identified chemical functionality is not capable of disrupting non-covalent bonding within the supramolecular synthon formed by the supramolecular synthon formed by the active pharmaceutical ingredient, and wherein the selected chemical functionality is capable of forming a noncovalent bond to the supramolecular synthon formed by the active pharmaceutical ingredient;
- and
- (d) identifying co-crystal formers having chemical functionalities that are complementary with the active pharmaceutical ingredient.
27-28. (canceled)
A method for identifying complementary chemical functionalities in order to form a desired supramolecular synthon, said method comprising:
- (a) evaluating the structure of an active pharmaceutical ingredient;
- (b) determining whether the active pharmaceutical ingredient contains chemical functionalities capable of forming supramolecular synthons with itself;
- (c) identifying from a plurality of chemical functionalities that are known to form supramolecular synthons at least one functionality that will form a supramolecular synthon with the active pharmaceutical ingredient, wherein the identified chemical functionality is capable of disrupting non-covalent bonding within the supramolecular synthon formed by the active pharmaceutical ingredient, and wherein the selected chemical functionality is capable of forming a noncovalent bond to a complementary chemical functionality on the active pharmaceutical ingredient;
- and
- (d) identifying co-crystal formers having chemical functionalities that are complementary with the active pharmaceutical ingredient.
31-32. (canceled)
A method for identifying complementary chemical functionalities in order to form a desired supramolecular synthon, said method comprising:
- (a) evaluating the structure of an active pharmaceutical ingredient;
- (b) determining whether the active pharmaceutical ingredient contains chemical functionalities capable of forming supramolecular synthons with different molecules;
- (c) identifying from a plurality of chemical functionalities that are known to form supramolecular synthons at least one functionality that will form a supramolecular synthon with the active pharmaceutical ingredient, and wherein the selected chemical functionality is capable of forming a noncovalent bond to a complementary chemical functionality on the active pharmaceutical ingredient;
- and
- (d) identifying co-crystal formers having chemical functionalities that are complementary with the active pharmaceutical ingredient.
35-36. (canceled)
Dependencies are inferred from the claim text.